关键词： AASLD, American Association for the Study of Liver Diseases ADV, adefovir dipivoxil ALT, alanine aminotransferase APASL, Asian Pacific Association for the Study of the Liver ART, antiretroviral therapy AST, aspartate aminotransferase Anti-HBe, antibodies to hepatitis B envelope antigen CBC, complete blood count CDC, Center for Disease Control CHB, chronic hepatitis B CU-HCC, Chinese University-Hepatocellular Carcinoma DAA, direct-acting antiviral DILI, drug induced liver injury DNA, deoxyribonucleic acid EASL, European Association for the Study of the Liver ETV, entecavir GAG-HCC, Guide with Age, Gender, HBV DNA, Core Promoter Mutations and Cirrhosis-Hepatocellular Carcinoma GGT, gamma-glutamyl transferase GRADE, Grading of Recommendations Assessment Development and Evaluation HBIG, hepatitis B immune globulin HBV, hepatitis B virus HBeAg, hepatitis B envelope antigen HCC, hepatocellular carcinoma HCV, hepatitis C virus HDV, hepatitis D virus HIV, human immunodeficiency virus IFN-α, interferon alpha INASL, Indian National Association for Study of the Liver INR, international normalized ratio KASL, Korean Association for the Study of the Liver LAM, lamivudine NA, nucleos(t)ide analogue PAGE-B, platelets, age, gender—hepatitis B PVNR, primary virological non-response PVR, partial virological response PegIFN-α, pegylated interferon alpha RCT, randomized controlled trial REACH-B, risk estimation for hepatocellular carcinoma in chronic hepatitis B SOVR, sustained off-therapy virological response TAF, tenofovir alafenamide TDF, tenofovir disoproxil fumarate TDV, telbivudine TSH, thyroid-stimulating hormone VR, virologic response WHO, World Health Organization anti-HBs, antibody to hepatitis B surface antigen cccDNA, covalently closed circular DNA chronic hepatitis cirrhosis eGFR, estimated glomerular filtration rate hepatitis B jaundice liver failure

来  源：   DOI：10.1016/j.jceh.2017.12.001   PDF(Sci-hub)   PDF(Pubmed)

Abstract：
Hepatitis B Virus (HBV) infection is one of the major causes of morbidity, mortality and healthcare expenditure in India. There are no Indian consensus guidelines on prevention, diagnosis and management of HBV infection. The Indian National Association for Study of the Liver (INASL) set up a taskforce on HBV in 2016, with a mandate to develop consensus guidelines for diagnosis and management of HBV infection, relevant to disease patterns and clinical practices in India. The taskforce first identified contentious issues on various aspects of HBV management, which were allotted to individual members of the taskforce who reviewed them in detail. A 2-day round table discussion was held on 11th and 12th February 2017 at Port Blair, Andaman & Nicobar Islands, to discuss, debate, and finalize the consensus statements. The members of the taskforce reviewed and discussed the existing literature threadbare at this meeting and formulated the \'INASL position statements\' on each of the issues. The evidence and recommendations in these guidelines have been graded according to the Grading of Recommendations Assessment Development and Evaluation (GRADE) system with minor modifications. The strength of recommendations (strong: 1, weak: 2) thus reflects the quality (grade) of underlying evidence (A, B, C, D). We present here the INASL position statements on prevention, diagnosis and management of HBV in India.
摘要：
乙型肝炎病毒（HBV）感染是发病的主要原因之一，印度的死亡率和医疗保健支出。印度没有关于预防的共识准则，HBV感染的诊断和管理。印度全国肝脏研究协会（INASL）于2016年成立了HBV工作组，其任务是制定HBV感染诊断和管理的共识指南，与印度的疾病模式和临床实践有关。工作组首先确定了HBV管理各个方面的有争议的问题，分配给工作组的个别成员，他们对它们进行了详细的审查。2017年2月11日和12日在布莱尔港举行了为期两天的圆桌讨论，安达曼和尼科巴群岛，讨论,辩论,并最终确定共识声明。工作组成员在本次会议上审查并讨论了现有文献，并就每个问题制定了“INASL立场声明”。这些指南中的证据和建议已根据建议评估开发和评估（GRADE）系统进行了分级，但略有修改。因此，建议的强度（强：1，弱：2）反映了基础证据的质量（等级）（A，B,C,D).我们在这里介绍INASL关于预防的立场声明，印度HBV的诊断和管理。
公众号